Isabella Cattani-Cavalieri

Isabella Cattani-Cavalieri

Auto-generated profile, based on publicly available information

Isabella Cattani-Cavalieri

Chapman University School of Pharmacy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2017 in Inflammation
Verified
Journal Article
Closed access
PDF file
ICIsabella Cavalieri
Isabella Cavalieri
ARAdriane Graça Reis
Adriane Graça Reis
EKEmanuel Kennedy-Feitosa
Emanuel Kennedy-Feitosa
VPVanessa Pinho-Ribeiro
Vanessa Pinho-Ribeiro
Manuella LanzettiManuella Lanzetti
Manuella Lanzetti
Samuel ValencaSamuel Valenca
Samuel Valenca

18 May 2023 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
ICIsabella Cavalieri
Isabella Cavalieri
YLYue Li
Yue Li
JMJordyn Margolis
Jordyn Margolis
ABAmy Bogard
Amy Bogard
MRMoom Rahman Roosan
Moom Rahman Roosan
RORennolds Ostrom
Rennolds Ostrom
ID 14791 Poster Board 78 Human airway smooth muscle (HASM) is the primary target of ssAR agonists used to control airway hypercontractility in asthma and chronic obstructive pulmonary disease (COPD). ss2AR agonism induces the production of cyclic adenosine monophosphate (cAMP) by adenylyl cyclases (ACs), which activates PKA and leads a myriad of cellular effects including bronchodilation. Several other GPCRs expressed in HASM cells transduce extracellular signals through cAMP but these receptors elicit different cellular responses, suggesting cAMP signaling is compartmentized. Previous work has shown these GPCR can couple to specific ACs that are localized in distinct membrane microdomains, partly explaining this compartmentation. However, little is known about the downstream steps of cAMP compartmentation. We developed a proteomic approach to define the downstream signaling networks emanating from specific AC isoforms in HASM. Stable Isotope Labeling of Amino acids in Cell culture (SILAC) was used to identify and quantify phosphorylated proteins in HASM overexpressing AC2 or AC6 after a short stimulus of AC activity by forskolin. Phosphopeptides were analyzed by LC-MS/MS and the quantitative difference between light and heavy labeled SILAC pairs represented the change in abundance of that peptide caused by forskolin treatment. Forskolin-stimulated cAMP production in control (lacZ) HASM displayed a logEC50 of -8.14 ± 0.04 and an Emax of 0.328 ± 0.010. In AC2-overexpressing cells, forskolin potency as efficacy was moderately increased (logEC50 of -8.79 ± 0.02 and an Emax of 0.498 ± 0.007). AC6 overexpression led to similar increases in forskolin responses (logEC50 of -8.67 ± 0.12 and an Emax of 0.509 ± 0.030). Using a subtractive analysis to identify effects of just the overexpressed AC isoform (over that natively expressed in control HASM), we found 14 differentially phosphorylated proteins (DPPs) linked to AC2 signaling and 34 DPPs linked to AC6 signaling. AC2 and AC6 groups showed in common 4 up- and 3 down-regulated phosphorylated proteins (using fold change ≥ 1.5 or ≤ 1/1.5 of the light/heavy ratio with p-values <0.05, n=3). The Gene Set Enrichment Analysis (GSEA) was used to identify statistically significant pathways with a p-value <0.05 reflected with enrichment scores. We identified 11 and 78 significant pathways using AC2 and AC6 differentially regulated proteins. Analysis of the phosphorylated peptides with the STRING protein interaction tool showed that AC2 signaling is more associated with modifications in RNA/DNA binding proteins and microtubule/spindle body proteins while AC6 signaling is associated with proteins regulating autophagy, calcium-calmodulin signaling, Rho GTPases and cytoskeletal regulation. One protein, OFD1, was regulated in opposite directions, with serine 899 phosphorylation increased in the AC6 condition 1.5-fold while in the AC2 condition it decreased to 0.46-fold. In conclusion, quantitative phosphoproteomics is a powerful tool for deciphering the complex signaling networks resulting from discreet signaling events that occur in cAMP compartments. Our data show key differences in the cAMP signaling networks generated by AC2 and AC6 and imply that distinct cellular responses are regulated by these two compartments. Funding information: GM107094

11 March 2021
Verified
Conference Paper
Open access
ICIsabella Cavalieri
Isabella Cavalieri
HVHelber da Maia Valença
Helber da Maia Valença
Samuel ValencaSamuel Valenca
Samuel Valenca
Martina SchmidtMartina Schmidt
Martina Schmidt
Background: Air pollution is caused mainly by diesel burning and is associated to increased morbidity and mortality due the potential adverse health effects caused by inflammation and oxidative stress. Dimethyl fumarate (DMF) is a fumaric acid ester and acts as an anti-oxidative and anti-inflammatory. We aimed to investigate the therapeutic effect of DMF against pulmonary damage caused by diesel exhaust particles (DEP) chronic exposure of mice. Methods: Mice were treated with DEP (30 μg/mice) of by intranasal instillation over 60 consecutive days. After day 30, the animals were treated with 30 mg/kg of DMF by gavage until the end of the experiment. Results: We demonstrated the reduction of total cell number in DEP+DMF than in DEP group. Importantly, DMF treatment was able to reduce the lung injury caused by DEP exposure. Intracellular total ROS, peroxynitrite (OONO) and nitric oxide (NO) levels reduced in DEP+DMF than in DEP group. The protein expression of kelch-like ECH-associated protein 1 (Keap-1) and nuclear factor κB (NF-κB) reduced in DEP+DMF compared to DEP group. NF-κB decreased in DEP+DMF than in control group. Nitrotyrosine, glutathione peroxidase-1/2 (GPx-1/2) and catalase expression decreased in DEP+DMF than in DEP group. Conclusion: In conclusion, our study is the first to demonstrates that treatment with DMF effectively ameliorates DEP-induced lung injury, inflammation, and oxidative and nitrosative stress. Since air pollution poses a common and serious health threat world-wide, the identification of DMF as a potent antioxidant and anti-inflammatory agent in the lungs could benefit the development of therapeutic approaches against airway pollution-associated malignancies.